CAR T-cell immunotherapy in minority patients with lymphoma

Researchers analyzed the prevalence and clinical outcomes of patients with large B-cell lymphomas treated with commercial CAR T-cell immunotherapy at two geographically and socioeconomically different institutions. They found that access by minority health populations (MHP) to commercial CAR-T immunotherapy appeared to be reduced compared with non-MHPs. Although clinical outcomes appeared the same between patient populations, researchers concluded the small sample size merited further research to understand the impact of racial disparities on access to CAR-T therapy.